Previous 10 | Next 10 |
ALPHARETTA, Ga., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its licen...
ALPHARETTA, Ga., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Las...
Clearside Biomedical (NASDAQ: CLSD ) announced that its licensing partner, REGENXBIO (NASDAQ: RGNX ) has dosed the first patient in its Phase 2 clinical trial to evaluate the suprachoroidal delivery of RGX-314, using Clearside’s SCS Microinjector for the treatment of wet age-rel...
ALPHARETTA, Ga., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its licen...
Clearside Biomedical (NASDAQ: CLSD ) perks 7% premarket after securing three additional patents in the U.S. and Europe. More news on: Clearside Biomedical, Inc., Healthcare stocks news, Stocks on the move, Read more ...
ALPHARETTA, Ga., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the recent issua...
Clearside Biomedical, Inc. (CLSD) Q2 2020 Earnings Conference Call August 10, 2020 04:30 PM ET Company Participants Jenny Kobin - Head, Investor Relations George Lasezkay - President & Chief Executive Officer Thomas Ciulla - Chief Medical Officer & Chief Development Offic...
What Do Analysts Think About These Penny Stocks To Buy For Less Than $3? As the saying goes with penny stocks : just because they’re low-priced doesn’t mean they’re “cheap”. This is a distinction new traders won’t understand until they find penny sto...
Clearside Biomedical (NASDAQ: CLSD ) : Q2 GAAP EPS of -$0.13 misses by $0.06 . More news on: Clearside Biomedical, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
- IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) - - Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs - - Engaged New Contract Manufacturer for XIPERE ™ - - Management to Host Webcast and Conference Call Today at 4:...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...